BJMO - volume 13, issue 8, december 2019
G. El Hachem MD, J. Kerger MD
After last year’s ESMO meeting in Munich, the recent ESMO Congress in Barcelona again proved to be a ‘grand cru’ in gynaecological cancer, with the confirmation of the role of maintenance therapy with PARP inhibitors in first-line therapy of advanced ovarian cancer, even beyond BRCA mutation. Additionally, recent progress in the management of endometrial and cervical cancer will be highlighted in this overview.
Read moreBJMO - volume 13, issue 3, may 2019
G. El Hachem MD, Y. Jounblat MD, A. Awada MD, PhD, A. Gombos MD
Triple-negative breast cancer is a heterogeneous subtype of breast carcinoma lacking the expression of oestrogen, progesterone and human epidermal growth factor 2 receptors. For many decades, cytotoxic chemotherapy has been the standard of care offering only a short-living disease control. Knowing its poor outcome and aggressive behaviour, researchers are trying to find new therapeutic options hoping to improve the survival of this population. Many cytotoxic and targeted therapies were tested without major benefit. However, in the era of molecular and mutational classification of tumours, as well as the immune mediated mechanisms of proliferation and progression, the trials are currently oriented towards the identification of potential targets in the tumoral heterogenic environment. Here, we present a review of literature concerning the potential anti-neoplastic options and novel therapies for metastatic triple-negative breast cancers: new cytotoxic agents, new targeted therapies, anti-angiogenic agents, antibody-drug conjugates, poly-ADP ribose transferase inhibitors and immunotherapy. Many agents are promising, yet not powerful enough to get approvals for use into clinical practice.
(BELG J MED ONCOL 2019;13(3):84–92)
Read moreBJMO - volume 12, issue 3, february 2018
G. El Hachem MD, C. Jungels MD
BJMO - volume 12, issue 3, february 2018
G. El Hachem MD, L. Polastro , J. Kerger MD
BJMO - volume 12, issue 3, february 2018
Y. Jounblat MD, G. El Hachem MD, A. Drowart , J. Kerger MD
BJMO - volume 11, issue 7, november 2017
G. El Hachem MD, J. Kerger MD
With more than 24,000 attendees, ESMO 2017 was the biggest oncology meeting ever organised in Europe. In the gynaecological cancer domain, there were some potentially practice-changing presentations in ovarian and cervical cancer, whereas new data in endometrial cancer were very sparse.
(BELG J ONCOL 2017;11(7):301–308)
Read moreBJMO - volume 11, issue 6, october 2017
G. El Hachem MD, C. Jungels MD, R. De Wind , J. Kerger MD
Uterine carcinosarcomas or mixed malignant mullerian tumours (MMMT) are rare gynaecological tumours with mixed carcinomatous and sarcomatous components. They are aggressive with a high risk of loco-regional and distant recurrence. Central nervous system (CNS) invasion by gynaecological malignancies is unusual and is exceptional in MMMT. There are eight reported cases of CNS metastases secondary to uterine MMMT with six cases of brain and two cases of spinal cord metastases. Here we report the case of a 50 year old woman, previously healthy, who was diagnosed with an aggressive heterologous 17x14x10 cm MMMT of the uterus, invading the whole endometrial wall, with lympho-vascular invasion and associated rhabdomyosarcoma elements. She underwent radical surgical resection followed by adjuvant radiation and chemotherapy. She recurred for the first time locally, and was treated with wide surgical resection. Six months later, she developed metastases in supra and infra-diaphragmatic lymph nodes, peritoneum and lungs. While being on palliative chemotherapy for her disseminated disease, she suffered from headache, and unfortunately 4 brain metastatic lesions were seen on brain MRI. Clinicians must be aware of this exceptional metastatic location of MMMT. However, there are no guidelines to screen, prevent or treat CNS metastases secondary to MMMT.
(BELG J MED ONCOL 2017;11(6):284–288)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
